S&P 500   3,233.72 (-3.12%)
DOW   28,056.25 (-3.23%)
QQQ   221.70 (-3.72%)
AAPL   299.68 (-4.27%)
FB   199.65 (-5.01%)
MSFT   171.85 (-3.77%)
GOOGL   1,423.08 (-4.07%)
AMZN   2,002.96 (-4.44%)
CGC   20.53 (-6.21%)
NVDA   276.96 (-5.82%)
BABA   205.52 (-3.33%)
MU   54.34 (-4.65%)
GE   11.91 (-2.86%)
TSLA   835.49 (-7.27%)
AMD   49.33 (-7.41%)
T   38.25 (-0.78%)
NFLX   365.44 (-3.85%)
BAC   32.76 (-4.66%)
DIS   131.41 (-5.44%)
GILD   72.58 (+4.13%)
S&P 500   3,233.72 (-3.12%)
DOW   28,056.25 (-3.23%)
QQQ   221.70 (-3.72%)
AAPL   299.68 (-4.27%)
FB   199.65 (-5.01%)
MSFT   171.85 (-3.77%)
GOOGL   1,423.08 (-4.07%)
AMZN   2,002.96 (-4.44%)
CGC   20.53 (-6.21%)
NVDA   276.96 (-5.82%)
BABA   205.52 (-3.33%)
MU   54.34 (-4.65%)
GE   11.91 (-2.86%)
TSLA   835.49 (-7.27%)
AMD   49.33 (-7.41%)
T   38.25 (-0.78%)
NFLX   365.44 (-3.85%)
BAC   32.76 (-4.66%)
DIS   131.41 (-5.44%)
GILD   72.58 (+4.13%)
S&P 500   3,233.72 (-3.12%)
DOW   28,056.25 (-3.23%)
QQQ   221.70 (-3.72%)
AAPL   299.68 (-4.27%)
FB   199.65 (-5.01%)
MSFT   171.85 (-3.77%)
GOOGL   1,423.08 (-4.07%)
AMZN   2,002.96 (-4.44%)
CGC   20.53 (-6.21%)
NVDA   276.96 (-5.82%)
BABA   205.52 (-3.33%)
MU   54.34 (-4.65%)
GE   11.91 (-2.86%)
TSLA   835.49 (-7.27%)
AMD   49.33 (-7.41%)
T   38.25 (-0.78%)
NFLX   365.44 (-3.85%)
BAC   32.76 (-4.66%)
DIS   131.41 (-5.44%)
GILD   72.58 (+4.13%)
S&P 500   3,233.72 (-3.12%)
DOW   28,056.25 (-3.23%)
QQQ   221.70 (-3.72%)
AAPL   299.68 (-4.27%)
FB   199.65 (-5.01%)
MSFT   171.85 (-3.77%)
GOOGL   1,423.08 (-4.07%)
AMZN   2,002.96 (-4.44%)
CGC   20.53 (-6.21%)
NVDA   276.96 (-5.82%)
BABA   205.52 (-3.33%)
MU   54.34 (-4.65%)
GE   11.91 (-2.86%)
TSLA   835.49 (-7.27%)
AMD   49.33 (-7.41%)
T   38.25 (-0.78%)
NFLX   365.44 (-3.85%)
BAC   32.76 (-4.66%)
DIS   131.41 (-5.44%)
GILD   72.58 (+4.13%)
Log in

NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, Forecast & News

$6.76
0.00 (0.00 %)
(As of 02/24/2020 12:05 PM ET)
Today's Range
$6.76
Now: $6.76
$6.76
50-Day Range
$6.06
MA: $6.47
$6.76
52-Week Range
$2.06
Now: $6.76
$7.01
VolumeN/A
Average Volume8.44 million shs
Market Capitalization$946.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone203-624-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.92 per share

Profitability

Net Income$-70,270,000.00

Miscellaneous

Employees56
Market Cap$946.72 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive ACHN News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter.


Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.02. View Achillion Pharmaceuticals' Earnings History.

When is Achillion Pharmaceuticals' next earnings date?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Achillion Pharmaceuticals.

What price target have analysts set for ACHN?

5 brokers have issued 12-month price objectives for Achillion Pharmaceuticals' stock. Their forecasts range from $2.50 to $6.30. On average, they anticipate Achillion Pharmaceuticals' share price to reach $5.03 in the next year. This suggests that the stock has a possible downside of 25.5%. View Analyst Price Targets for Achillion Pharmaceuticals.

What is the consensus analysts' recommendation for Achillion Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.

Has Achillion Pharmaceuticals been receiving favorable news coverage?

Media coverage about ACHN stock has been trending negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the next few days. View News Stories for Achillion Pharmaceuticals.

Are investors shorting Achillion Pharmaceuticals?

Achillion Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 16,380,000 shares, an increase of 16.3% from the January 15th total of 14,080,000 shares. Based on an average daily volume of 3,710,000 shares, the short-interest ratio is currently 4.4 days. Approximately 12.0% of the shares of the company are sold short. View Achillion Pharmaceuticals' Current Options Chain.

Who are some of Achillion Pharmaceuticals' key competitors?

What other stocks do shareholders of Achillion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHK), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Iconix Brand Group (ICON), Celldex Therapeutics (CLDX), Edap Tms (EDAP) and ACADIA Pharmaceuticals (ACAD).

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph Truitt, Pres, CEO & Director (Age 54)
  • Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)
  • Mr. Brian R. Di Donato, CFO, SVP & Treasurer (Age 52)
  • Mr. Paul Firuta, Exec. VP & COO (Age 53)
  • Dr. Kevin P. Malobisky, Sr. VP of Regulatory Affairs, Quality & Compliance

Who are Achillion Pharmaceuticals' major shareholders?

Achillion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include ARP Americas LP (5.37%), Magnetar Financial LLC (3.92%), State Street Corp (3.67%), Renaissance Technologies LLC (3.02%), UBS Group AG (2.76%) and CNH Partners LLC (2.26%). Company insiders that own Achillion Pharmaceuticals stock include David Scheer and Joseph Truitt. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Which major investors are selling Achillion Pharmaceuticals stock?

ACHN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., UBS Group AG, Candriam Luxembourg S.C.A., Public Sector Pension Investment Board, South Dakota Investment Council, Bank of America Corp DE, Raymond James & Associates and Rafferty Asset Management LLC. Company insiders that have sold Achillion Pharmaceuticals company stock in the last year include David Scheer and Joseph Truitt. View Insider Buying and Selling for Achillion Pharmaceuticals.

Which major investors are buying Achillion Pharmaceuticals stock?

ACHN stock was acquired by a variety of institutional investors in the last quarter, including ARP Americas LP, Magnetar Financial LLC, CNH Partners LLC, Boxer Capital LLC, Alliancebernstein L.P., Credit Suisse AG, State Street Corp and Fairmount Funds Management LLC. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy shares of Achillion Pharmaceuticals?

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of ACHN stock can currently be purchased for approximately $6.76.

How big of a company is Achillion Pharmaceuticals?

Achillion Pharmaceuticals has a market capitalization of $946.72 million. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe.View Additional Information About Achillion Pharmaceuticals.

What is Achillion Pharmaceuticals' official website?

The official website for Achillion Pharmaceuticals is http://www.achillion.com/.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.


MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  487 (Vote Outperform)
Underperform Votes:  438 (Vote Underperform)
Total Votes:  925
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: What is the Coverage Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel